Current therapies in Hodgkin's disease

K. E. Kogel, J. W. Sweetenham

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.

Original languageEnglish (US)
Pages (from-to)S19-S27
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue numberSUPPL. 1
StatePublished - Jun 1 2003
Externally publishedYes


  • Early-stage disease
  • Hodgkin's disease
  • Long-term toxicity
  • Treatment

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Current therapies in Hodgkin's disease'. Together they form a unique fingerprint.

Cite this